Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [11C]PBT2.

Krishnan HS, Bernard-Gauthier V, Placzek MS, Dahl K, Narayanaswami V, Livni E, Chen Z, Yang J, Collier TL, Ran C, Hooker JM, Liang SH, Vasdev N.

Mol Pharm. 2018 Feb 5;15(2):695-702. doi: 10.1021/acs.molpharmaceut.7b00936. Epub 2018 Jan 22.

PMID:
29298483
2.

PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primates.

Liang SH, Holland JP, Stephenson NA, Kassenbrock A, Rotstein BH, Daignault CP, Lewis R, Collier L, Hooker JM, Vasdev N.

ACS Chem Neurosci. 2015 Apr 15;6(4):535-41. doi: 10.1021/acschemneuro.5b00055. Epub 2015 Mar 24.

3.

High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.

Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ, Sherman P, Quesada CA, Hockley BG, Kilbourn MR, Albin RL, Frey KA, Scott PJ.

ACS Chem Neurosci. 2014 Aug 20;5(8):718-30. doi: 10.1021/cn500103u. Epub 2014 Jun 16.

4.

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group.

Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.

PMID:
18672400
5.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2014 Feb 21;(2):CD005380. doi: 10.1002/14651858.CD005380.pub5. Review.

PMID:
24563468
6.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2012 May 16;(5):CD005380. doi: 10.1002/14651858.CD005380.pub4. Review. Update in: Cochrane Database Syst Rev. 2014;(2):CD005380.

7.

Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease.

Cai L, Liow JS, Zoghbi SS, Cuevas J, Baetas C, Hong J, Shetty HU, Seneca NM, Brown AK, Gladding R, Temme SS, Herman MM, Innis RB, Pike VW.

J Med Chem. 2008 Jan 10;51(1):148-58. Epub 2007 Dec 14.

PMID:
18078311
8.

Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology.

Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, Shiomi S, Muto M, Ito T, Furutsuka K, Yamasaki T, Yui J, Xie L, Ono M, Hatori A, Nemoto K, Suhara T, Higuchi M, Zhang MR.

J Nucl Med. 2014 Sep;55(9):1532-8. doi: 10.2967/jnumed.114.139550. Epub 2014 Jun 24.

9.

Practical Radiosynthesis and Preclinical Neuroimaging of [11C]isradipine, a Calcium Channel Antagonist.

Rotstein BH, Liang SH, Belov VV, Livni E, Levine DB, Bonab AA, Papisov MI, Perlis RH, Vasdev N.

Molecules. 2015 May 26;20(6):9550-9. doi: 10.3390/molecules20069550.

10.

Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.

Yousefi BH, Manook A, Drzezga A, von Reutern B, Schwaiger M, Wester HJ, Henriksen G.

J Med Chem. 2011 Feb 24;54(4):949-56. doi: 10.1021/jm101129a. Epub 2011 Jan 28.

PMID:
21275403
11.

Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase.

Hicks JW, Parkes J, Sadovski O, Tong J, Houle S, Vasdev N, Wilson AA.

Nucl Med Biol. 2013 Aug;40(6):740-6. doi: 10.1016/j.nucmedbio.2013.04.008. Epub 2013 May 31.

12.

18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase.

Horti AG, Wang Y, Minn I, Lan X, Wang J, Koehler RC, Alkayed NJ, Dannals RF, Pomper MG.

J Nucl Med. 2016 Nov;57(11):1817-1822. Epub 2016 Jul 14.

13.

Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2.

Slavik R, Müller Herde A, Haider A, Krämer SD, Weber M, Schibli R, Ametamey SM, Mu L.

J Neurochem. 2016 Sep;138(6):874-86. doi: 10.1111/jnc.13716. Epub 2016 Aug 2.

14.

Evaluation of [11C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT.

Pan ML, Mukherjee MT, Patel HH, Patel B, Constantinescu CC, Mirbolooki MR, Liang C, Mukherjee J.

Synapse. 2016 Apr;70(4):163-76. doi: 10.1002/syn.21893. Epub 2016 Feb 11.

15.

Synthesis and preclinical evaluation of an 18F labeled PDE7 inhibitor for PET neuroimaging.

Thomae D, Servaes S, Vazquez N, Wyffels L, Dedeurwaerdere S, Van der Veken P, Joossens J, Augustyns K, Stroobants S, Staelens S.

Nucl Med Biol. 2015 Dec;42(12):975-81. doi: 10.1016/j.nucmedbio.2015.07.007. Epub 2015 Jul 29.

PMID:
26330158
16.

PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.

Cherny RA, Ayton S, Finkelstein DI, Bush AI, McColl G, Massa SM.

J Huntingtons Dis. 2012;1(2):211-9. doi: 10.3233/JHD-120029.

PMID:
25063332
17.

A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.

Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S, Salvado O, Bourgeat P, Perez K, Fowler C, Rembach A, Maruff P, Ritchie C, Tanzi R, Masters CL.

Alzheimers Dement (N Y). 2017 Nov 9;3(4):622-635. doi: 10.1016/j.trci.2017.10.001. eCollection 2017 Nov.

18.

Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5.

Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, Auberson YP, Gasparini F, Schubiger PA.

J Nucl Med. 2006 Apr;47(4):698-705.

19.

11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain.

Zhang MR, Kumata K, Maeda J, Yanamoto K, Hatori A, Okada M, Higuchi M, Obayashi S, Suhara T, Suzuki K.

J Nucl Med. 2007 Nov;48(11):1853-61.

20.

Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.

Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP.

Nucl Med Biol. 2009 May;36(4):411-7. doi: 10.1016/j.nucmedbio.2009.01.013. Epub 2009 Mar 26.

PMID:
19423009

Supplemental Content

Support Center